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Abstract
Background: Deficiency of the eighth component of complement (C8) is a very rare primary immunodeficiency,
associated with invasive, recurrent infections mainly caused by Neisseria species. We report functional and
immunochemical C8 deficiency diagnosed in three Albanian siblings who presented with severe meningococcal
infections at the age of 15 years, 4 years and 17 months, respectively. The youngest suffered serious complications
(necrosis of fingers and toes requiring amputation).
Methods: Functional activity of the classical, alternative and mannose-binding lectin complement pathways was
measured in serum from the 3 siblings and their parents (37-year-old woman and 42-year-old man). Forty healthy
subjects (20 males and 20 females aged 4–38 years) served as normal controls. Serum complement factors were
measured by haemolytic assays and immunoblotting. Sequence DNA analysis of the C8B gene was performed.
Results: Analyses of the three complement pathways revealed no haemolytic activity and also absence of C8beta
in serum samples from all three siblings. The genetic analysis showed that the three siblings were homozygous for
the p.Arg428* mutation in the C8B gene on chromosome 1p32 (MIM 120960). The parents were heterozygous for
the mutation and presented normal complement activities. A 2-year follow-up revealed no further infective
episodes in the siblings after antibiotic prophylaxis and meningococcal vaccination.
Conclusions: Complement deficiencies are rare and their occurrence is often underestimated. In presence of
invasive meningococcal infection, we highlight the importance of complement screening in patients and their
relatives in order to discover any genetic defects which would render necessary prophylaxis to prevent recurrent
infections and severe complications.
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Background
The terminal complement pathway comprises five pro-
teins which become combined together to form the
membrane attack complex (MAC) [1]. This is a major
effector mechanism of humoral immunity; however the
MAC cannot form if any of components are absent and
affected patients have liability to bacterial infections in-
cluding Neisseria meningitidis infections.
In particular, the 8th complement component (C8), to-
gether with C5, C6, C7 and C9, assemble on bacterial
membranes to form the lethal pore-like MAC. C8 is
composed of three subunits (alpha, beta and gamma)
which are encoded by three separate genes (C8A, C8B
and C8G). Complement deficiencies represent approxi-
mately 1–6 % of all primary immunodeficiencies but this
may go up to 10 % in certain communities [2–6]. In par-
ticular a recent study had shown that C8 deficiency
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represents 8 % of complement deficiencies across Eur-
ope [5]. The prevalence of congenital complement defi-
ciency has been calculated to be about 0.03 % in the
general European population, excluding MBL (mannose
binding lectin) deficiency which has been estimated to
occur in its homozygous form in about 5 % of the
population [2, 7]. Inherited deficiencies of terminal
complement components result in increased suscepti-
bility to infections, particularly Neisseria species.
However heterozygous carriers are not susceptible to
these infections [8].
Unlike in the general population, where the infections
mainly affect children in the first years of life, in patients
with C8 complement deficiency the average age of onset
was found to be 17 years and only 10 % of the cases
occurred before 5 years of age. Recurrent disease oc-
curred in 45 % [9]. Furthermore, some of these pa-
tients presented a milder course of the disease with a
5 to 10 fold decrease in the probability of death,
when compared to meningococcal disease (MD) in
the general population [9].
Here, we report a long history of invasive meningococ-
cal disease in three C8-deficient Albanian siblings and
severe complications in the youngest sister. The clinical
course was favourable after patients had received menin-
gococcal vaccination and antibiotic prophylaxis had been
started.
Methods
Patients
Three patients attended the University Hospital in 2013
for evaluation of suspected immunodeficiency. They
were Albanian siblings, a boy (16 years old) and two girls
(14 and 6 years old respectively) and they presented with
a long history of MD. Their parents, a 37-year-old
woman and a 42-year-old man, were apparently healthy.
All three siblings were subjected to in-depth investiga-
tions to rule out primary immunodeficiencies. Tests
showed normal values of serum immunoglobulins, IgG
subclasses, and T and B cells numbers and activity.
Functional activities of the classical and alternative path-
ways of complement were measured. Asplenia was ex-
cluded by abdominal ultrasound.
Forty healthy subjects (20 males and 20 females aged
4–38 years) served as normal controls for the comple-
ment studies.
Eligibility
The study was conducted following the ethical principles
of the Declaration of Helsinki, regulatory requirements
and the code of Good Clinical Practice. The parents of
the 3 patients gave their written informed consent for
genetic studies.
Functional tests for the classical, alternative and
mannose-binding lectin complement pathways
These tests were performed in accordance with the man-
ufacturer’s instructions (Wieslab Complement System;
Euro-Diagnostica, Malmö, Sweden) through the three
complement pathways with the terminal complement
complex C5b-9 used as the common detection system
[10]. The wells of the microtiter strips were coated with
specific activators of the classical, alternative or
mannose-binding lectin pathways. The serum samples
were diluted in buffer containing specific blockers in
order to ensure that only one pathway was activated
during incubation. The wells were then washed, and
C5b-9 was detected with a specific alkaline phosphatase-
labelled antibody against the neoantigen expressed on
C9 during C5b-9 formation. After a further washing
step, the specific antibodies were detected by means of
incubation with the alkaline phosphatase substrate solu-
tion. As the amount of complement activation correlates
with colour intensity and is measured in terms of ab-
sorbance, the results were expressed as percentages of
the activity of a standard sample (i.e. normal pooled
serum fixed at 100 %).
Haemolytic assay
This assay was done as previously described [11]. Briefly,
antibody-sensitized sheep erythrocytes (EA) were pre-
pared with sub-agglutinating amount of rabbit IgM anti-
bodies. Haemolytic activity was evaluated by mixing
dilutions of test sera in glucose veronal-buffered saline
(GVBS) with 50 μl of 1 % EAC1-3b (i.e. EA incubated with
a C5 deficient serum to form C3 convertase [C1-3b]) to a
final volume of 250 μl. After incubation at 37 °C for 30
min, red cell lysis was calculated by measuring the OD415.
Haemolytic activity was expressed as a percentage of lysis
induced by water.
Sodium dodecyl sulphate-polyAcrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting analysis
Serum samples were subjected to SDS-PAGE on a 10 %
gel under non-reducing conditions followed by electro-
phoretic transfer onto nitrocellulose membrane (Hybond
ECL, Amersham, Milano, Italy) using the semidry Semi-
phor transfer unit (Heifer Scientific Instruments, San
Francisco, CA). The membranes were incubated with 1/
1000 goat IgG anti-C8 (Quidel, San Diego, CA, USA) for
1 h at 37 °C followed by 1/2,000 AP-conjugated anti-
goat Ig (Sigma–Aldrich) for 1 h at 37 °C. The enzymatic
reaction was developed as previously described [12]
Enzyme-linked immunosorbent assay (ELISA) for C8
C8 was measured in serum samples by a sandwich ELISA
using goat IgG anti-C8 to bind C8 and the same poly-
clonal antibody labeled with biotin to reveal bound C8
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followed by AP-conjugated streptavidin (Sigma–Aldrich).
The enzymatic reaction was developed using PNPP
(Sigma–Aldrich) as previously described [13].
Genetic analysis
Genomic DNA was amplified by PCR using primers de-
signed to amplify the coding region and the intron/exon
boundaries of the 12 exons of the C8B gene. PCR has
been performed using the conditions and primers re-
ported by Arnold et al. [14].
The PCR products were visualized on a 2 % agarose
gel and purified using ExoSAP-IT enzymatic PCR clean
up system (Affymetrix, Santa Clara CA). The purified
products were then sequenced with the Big Dye Termin-
ator kit (Applied Biosystems, Foster City, CA) and ana-
lysed on an ABI PRISM 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA).
Results
Clinical features
The first patient (patient 1) is a 16-year-old male with a
clinical history of sepsis due to nongroupable Neisseria
meningitides (capsule null locus strain – serotype 25) at
the age of 15 years. The clinical course was favourable
and he was discharged in good clinical conditions after
10 days of intravenous antibiotic therapy. His two sisters
had a history of previous meningococcal sepsis episodes
also due to Neisseria meningitidis. The first sister (pa-
tient 2), aged 14, had suffered from MD at the age of 4
years (10 years before), while the younger sister (patient
3), aged 6 years old, had suffered from sepsis due to
Neisseria meningitidis (serogroup B-serotype 14) at 17
months of age (5 years before); this was complicated by
necrosis of fingers and toes which required amputation.
The parents were not related to each other and did not
have histories of severe infections.
Laboratory findings
Complement analyses revealed undetectable functional
activity of the classical, alternative and lectin pathways
in all the three patients. Complement activity in the
parents was normal for all the three pathways (Table 1).
Further analyses were performed after recovery. The test
of complement activity showed C8 deficiency in all sib-
lings. These data were obtained with a haemolytic assay
and adding sera from patients with previously character-
ized single complement component deficiencies. There
were a clear and specific absence of the beta chains of
C8 in siblings’ sera; the activities were restored by adding
purified human C8 in the same lytic test (Table 2).
Moreover the deficiency of the C8 beta subunit in
these patients was confirmed by western blot using anti-
C8 antibody. The lane of C8 beta in the patient’s sera
was absent while in the parents’ sera was present but re-
duced in amount (Fig. 1, lower panel). In the three pa-
tients, serum levels of C8 antigen, tested on 5 dilutions,
resulted 13.00 ± 0.64 μg/ml, 12.00 ± 0.86 μg/ml and
15.00 ± 1.17 μg/ml, respectively, whereas in the parents,
C8 serum levels were 52.00 ± 2.29 μg/ml (mother) and
34.00 ± 2.24 μg/ml (father). In normal human plasma,
C8 serum levels were 72.50 ± 3.54 μg/ml (Fig. 1, upper
panel).
Sequence analyses of exon 1–12 of the C8B gene on
chromosome 1p32 in the 3 siblings revealed the pres-
ence of the nucleotide substitution, c.1282C>T that in-
troduces a premature stop codon (p.Arg428*.) in exon 9
responsible for most reported cases of C8 beta deficiency
(MIM 120960) [15]. The parents were heterozygous for
the same mutation (Fig. 2).
Treatment and course
After the diagnosis has been made the patients were im-
munized with the quadrivalent meningococcal conjugate
vaccine (Menveo®, MenACWY-CRM; Novartis Vaccines
and Diagnostics S.r.l., Siena, Italy) and as soon as pos-
sible with the vaccine against N. meningitides serogroup
B (Bexero®, Novartis Vaccines and Diagnostics S.r.l.,
Siena, Italy). Antibiotic prophylaxis with amoxicillin was
also started. They had no further episodes in the last
two years.
Table 1 Activity of the three complement pathways in the
three patients and their parents
Classical pathway Alternative pathway Lectin pathway
% % %
Patient 1 0 0 0
Patient 2 3 0 0
Patient 3 3 0 0
Mother 116 92 120
Father 122 91 125
Normal range 69–129 30–113 0–125
Table 2 Evaluation of complement deficiency by haemolytic
assay in serum from the 3 patients after adding serum with the
deficiency (def) of a single complement component
Patient’s serum + : Patient 1 Patient 2 Patient 3
(% of lysis) (% of lysis) (% of lysis)
C5 def serum 99 95 90
C6 def serum 94 95 79
C7 def serum 100 100 96
C8 alpha-gamma def serum 95 87 88
C8 beta def serum 0 0 0
C8 beta def serum + human C8 99 100 94
C9 def serum 100 100 100
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Fig. 1 Upper panel. Levels of C8 antigen in serum from the three patients and their parents as well as in normal human serum (NHS). Lower
panel. Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and immunoblotting analysis of C8 in serum from the three
patients and their parents as well as in NHS. The last lane on the right refers to molecular markers of known molecular weight
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Fig. 2 a Pedigree of the family. Filled symbols indicate affected individuals. The genotype for each family member is reported: +/− indicated the
heterozygous and −/− the homozygous for the mutant allele. b Direct fluorescent sequencing of the exon 9 of the C8B gene. A control
sequence homozygous for p.248Arg is reported along with the sequences from a heterozygous parent and a sib homozygous for the p.248Stop
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Discussion
The deficiency of C8 may be due to the lack of the beta
subunit or to the lack of alpha and gamma subunits
which are linked. The deficiency of C8 beta is more fre-
quent in the Caucasians, while the lack of alpha-gamma
chain is more frequent in Asian and African populations
[15]. The three affected siblings were homozygous for
the most commonly reported C8 beta mutation, namely
c.1282C>T leading to a premature stop codon
(p.Arg428*). This accounts for 85 % of mutations re-
ported as causing C8 beta deficiency [15]. Laboratory
data in the three patients and their parents are in agree-
ment with the genetic profile and we observed absence
of C8 activity and C8 beta subunit in the three patients
and normal C8 activity with reduced levels of C8 antigen
and C8 beta subunit in their parents. In the three pa-
tients, the absence of C8 activity is due to the absence of
the beta subunit while the low levels of C8 antigen are
due to the presence of the alpha and gamma subunits.
In their parents, even if C8 antigen levels are about half
of the normal, C8 activity is normal.
Deficiencies of complement components are rare dis-
eases and their diagnosis is often underestimated. The
meningococcal infection affects 40 % of individuals with
late components complement deficiencies and MD may
be the first manifestation of complement deficiency [16]
with mean age of onset 17 years; only 10 % of the cases
occur before 5 years of age [7]. Meningococcal infection
in two of our patients has occurred before 5 years, at 17
months and 4 years of age respectively. The delay in
diagnosis can lead the patient to develop recurrent men-
ingococcal infections; in the literature it is known that
another meningococcal infection occurs in 45 % of the
patients [17]. Although meningococcal infections in pa-
tients with deficiency of complement are generally not
lethal, the younger sister suffered serious complications
(necrosis of fingers and toes that required amputation).
These severe complications could have been avoided if
the correct diagnosis had been made after the first epi-
sode of meningococcal infection in the sister.
Testing all MD patients for complement function or
their DNA for selected gene defects known to circulate
in the area is an option [6]. Although serious sequelae
can develop because of any episode of meningococcal in-
fection it has been observed that patients who have suf-
fered recurrent MD infections become the worst
affected and can have the most long term sequelae [7]
and long term prophylaxis with penicillin was used to
protect patients from further episodes. A recent study
revealed that there is no agreement about of antibiotic
prophylaxis in these patients [5]. However previous
studies [18] demonstrated that meningococcal vaccin-
ation does not eliminate the risk of meningococcal dis-
ease and that in the individuals with inherited
deficiencies of terminal complement components, men-
ingococcal infection frequently involves unusual rare se-
rotypes [9, 19, 20]. In our patient 1, capsule null locus
strain, generally not pathogen, was found responsible for
MD. For these reasons we decided to prescribe prophy-
lactic amoxicillin to all three siblings. The lack of infect-
ive episodes during a 2-year follow-up further supports
our view.
Conclusion
This long family history highlights the importance of
early diagnosis and indicates the need for complement
evaluations in cases of invasive MD involving more than
one family member. As reported by Hoare et al. [21] the
presence of complement deficiency in children with MD
is rare event that doesn’t always warrant further investi-
gations. Indications to screen for complement deficien-
cies in patients with MD are, beyond family history as in
our case, repeated neisserial infections, infection with
unusual Neisseria serogroup, fulminant disease in males,
unusual course of the illness, coexisting angio-oedema
and autoimmune or connective tissue disorders [21].
The diagnosis of complement defects allows not only
the prevention of recurrent infections by antibiotics and
specific immunization of the patient, but also the dis-
closure, through appropriate genetic counselling, of
other affected family members in order to prevent infec-
tions by antibiotic prophylaxis and immunization also in
them.
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